Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024)

Historic Other Accumulated Expenses for Immunocore Holdings (IMCR) over the last 3 years, with Q1 2024 value amounting to $7.5 million.

  • Immunocore Holdings' Other Accumulated Expenses changed N/A to $7.5 million in Q1 2024 from the same period last year, while for Mar 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $6.0 million for FY2023, which is 6274.46% up from last year.
  • As of Q1 2024, Immunocore Holdings' Other Accumulated Expenses stood at $7.5 million.
  • Over the past 5 years, Immunocore Holdings' Other Accumulated Expenses peaked at $7.5 million during Q1 2024, and registered a low of $3.7 million during Q4 2022.
  • Over the past 3 years, Immunocore Holdings' median Other Accumulated Expenses value was $6.0 million (recorded in 2023), while the average stood at $5.7 million.
  • The largest annual percentage gain for Immunocore Holdings' Other Accumulated Expenses in the last 5 years was 6274.46% (2023), contrasted with its biggest fall of 6274.46% (2023).
  • Immunocore Holdings' Other Accumulated Expenses (Quarter) stood at $3.7 million in 2022, then soared by 62.74% to $6.0 million in 2023, then rose by 24.49% to $7.5 million in 2024.
  • Its Other Accumulated Expenses stands at $7.5 million for Q1 2024, versus $6.0 million for Q4 2023 and $3.7 million for Q4 2022.